Alaunos Therapeutics (TCRT) Competitors $2.63 -0.05 (-1.87%) Closing price 03:57 PM EasternExtended Trading$2.52 -0.12 (-4.37%) As of 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TCRT vs. EQ, LPTX, BFRG, BIVI, GLYC, MIRA, RLMD, INAB, MBRX, and CLRBShould you be buying Alaunos Therapeutics stock or one of its competitors? The main competitors of Alaunos Therapeutics include Equillium (EQ), Leap Therapeutics (LPTX), Bullfrog AI (BFRG), BioVie (BIVI), GlycoMimetics (GLYC), MIRA Pharmaceuticals (MIRA), Relmada Therapeutics (RLMD), IN8bio (INAB), Moleculin Biotech (MBRX), and Cellectar Biosciences (CLRB). These companies are all part of the "pharmaceutical products" industry. Alaunos Therapeutics vs. Equillium Leap Therapeutics Bullfrog AI BioVie GlycoMimetics MIRA Pharmaceuticals Relmada Therapeutics IN8bio Moleculin Biotech Cellectar Biosciences Equillium (NASDAQ:EQ) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, community ranking, institutional ownership, analyst recommendations, profitability and media sentiment. Do analysts recommend EQ or TCRT? Equillium presently has a consensus target price of $3.00, indicating a potential upside of 584.46%. Given Equillium's stronger consensus rating and higher possible upside, equities analysts plainly believe Equillium is more favorable than Alaunos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Equillium 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Alaunos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, EQ or TCRT? Equillium has a beta of 1.87, indicating that its stock price is 87% more volatile than the S&P 500. Comparatively, Alaunos Therapeutics has a beta of -0.74, indicating that its stock price is 174% less volatile than the S&P 500. Is EQ or TCRT more profitable? Alaunos Therapeutics has a net margin of 0.00% compared to Equillium's net margin of -10.05%. Equillium's return on equity of -20.68% beat Alaunos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Equillium-10.05% -20.68% -10.77% Alaunos Therapeutics N/A -267.77%-209.18% Does the media refer more to EQ or TCRT? In the previous week, Equillium had 4 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 6 mentions for Equillium and 2 mentions for Alaunos Therapeutics. Equillium's average media sentiment score of 0.20 beat Alaunos Therapeutics' score of 0.00 indicating that Equillium is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equillium 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alaunos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation and earnings, EQ or TCRT? Equillium has higher revenue and earnings than Alaunos Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEquillium$41.10M0.38-$13.34M-$0.23-1.91Alaunos Therapeutics$10K421.06-$35.14MN/AN/A Do institutionals and insiders hold more shares of EQ or TCRT? 27.0% of Equillium shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 30.3% of Equillium shares are held by company insiders. Comparatively, 5.1% of Alaunos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community favor EQ or TCRT? Equillium received 29 more outperform votes than Alaunos Therapeutics when rated by MarketBeat users. Likewise, 80.00% of users gave Equillium an outperform vote while only 58.33% of users gave Alaunos Therapeutics an outperform vote. CompanyUnderperformOutperformEquilliumOutperform Votes3680.00% Underperform Votes920.00% Alaunos TherapeuticsOutperform Votes758.33% Underperform Votes541.67% SummaryEquillium beats Alaunos Therapeutics on 13 of the 16 factors compared between the two stocks. Get Alaunos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCRT vs. The Competition Export to ExcelMetricAlaunos TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.21M$6.68B$5.44B$7.80BDividend YieldN/A3.17%5.43%4.30%P/E RatioN/A7.1422.1418.39Price / Sales421.06238.89389.70101.29Price / CashN/A65.6738.2034.62Price / Book0.676.266.664.18Net Income-$35.14M$142.48M$3.21B$247.71M7 Day Performance6.05%7.91%5.83%6.45%1 Month Performance68.70%-6.03%-4.31%-3.14%1 Year Performance-77.33%-0.96%17.83%5.40% Alaunos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCRTAlaunos Therapeutics0.6603 of 5 stars$2.63-1.9%N/A-77.3%$4.21M$10,000.000.0040EQEquillium2.8713 of 5 stars$0.44-3.1%$3.00+580.3%-73.7%$15.79M$41.10M-3.1640News CoveragePositive NewsGap DownLPTXLeap Therapeutics1.3094 of 5 stars$0.37+3.7%$4.92+1,218.1%-88.1%$15.47MN/A-0.1940BFRGBullfrog AI0.4046 of 5 stars$1.62-2.4%N/A-35.9%$15.25M$60,000.00-1.914BIVIBioVie1.3212 of 5 stars$0.82+3.3%$3.00+265.9%+76.9%$15.13MN/A-0.0810Positive NewsGap UpGLYCGlycoMimetics1.9397 of 5 stars$0.23+3.6%N/A-86.5%$14.71M$10,000.00-0.3950Analyst ForecastNews CoverageMIRAMIRA Pharmaceuticals2.4551 of 5 stars$0.87+0.1%$14.00+1,516.6%+14.3%$14.56MN/A-1.552Positive NewsRLMDRelmada Therapeutics3.5235 of 5 stars$0.44+37.5%$4.25+857.2%-80.9%$14.34MN/A-0.1510High Trading VolumeINABIN8bio3.0666 of 5 stars$0.17+2.9%$6.00+3,408.8%-82.5%$14.14MN/A-0.2320MBRXMoleculin Biotech2.206 of 5 stars$0.99+4.2%$6.00+506.1%-74.5%$13.86MN/A0.0020CLRBCellectar Biosciences2.1778 of 5 stars$0.30+3.0%$12.50+4,080.6%-89.8%$13.78MN/A-0.1710 Related Companies and Tools Related Companies Equillium Alternatives Leap Therapeutics Alternatives Bullfrog AI Alternatives BioVie Alternatives GlycoMimetics Alternatives MIRA Pharmaceuticals Alternatives Relmada Therapeutics Alternatives IN8bio Alternatives Moleculin Biotech Alternatives Cellectar Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TCRT) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alaunos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alaunos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TCRT Stock Free TCRT Stock Alerts